Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Investor Relations

Events & Presentations

Corporate Governance

Financial Information

Stock Information

Contact Us


All Releases
View Summary Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa
Dec 1, 2016
PDF 68.3 KB Add to Briefcase
View Summary Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16
Nov 10, 2016
PDF 9.2 KB Add to Briefcase
View Summary Aradigm Announces Third Quarter 2016 Financial Results
Nov 9, 2016
PDF 69.2 KB Add to Briefcase
View Summary Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm's Inhaled Ciprofloxacin
Oct 18, 2016
PDF 60.6 KB Add to Briefcase
View Summary Aradigm Announces Australian Research Council Funding to Develop Nanotechnologies Targeting Bacterial and Fungal Biofilms
Oct 7, 2016
PDF 61.7 KB Add to Briefcase
View Summary Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients
Sep 22, 2016
PDF 60.8 KB Add to Briefcase
View Summary Aradigm to Host Analyst Meeting and Webcast on September 26 in New York City
Sep 21, 2016
PDF 62.8 KB Add to Briefcase
View Summary Aradigm to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27
Sep 20, 2016
PDF 9.2 KB Add to Briefcase
View Summary Aradigm Announces Second Quarter 2016 Financial Results
Aug 10, 2016
PDF 69.2 KB Add to Briefcase
View Summary Two Presentations on Aradigm's Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference
May 11, 2016
PDF 64.9 KB Add to Briefcase
View Summary Aradigm Announces First Quarter 2016 Financial Results
May 10, 2016
PDF 68.5 KB Add to Briefcase
View Summary Aradigm Corporation Announces First Closing of Private Placement Offering of $23 Million Senior Convertible Notes Due 2021
Apr 26, 2016
PDF 11.8 KB Add to Briefcase
View Summary Aradigm Corporation Prices Private Placement of Senior Notes
Apr 22, 2016
PDF 11.5 KB Add to Briefcase
View Summary Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency
Mar 17, 2016
PDF 61.5 KB Add to Briefcase
View Summary Aradigm Announces Fourth Quarter 2015 and Full Year Financial Results
Mar 15, 2016
PDF 77.0 KB Add to Briefcase
View Summary Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016 on February 8
Feb 2, 2016
PDF 9.5 KB Add to Briefcase
View Summary Aradigm to Host Corporate Update Conference Call on January 6
Jan 5, 2016
PDF 62.4 KB Add to Briefcase
View Summary Aradigm Announces Third Quarter 2015 Financial Results
Nov 11, 2015
PDF 70.9 KB Add to Briefcase
View Summary Aradigm Corporation Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
Oct 13, 2015
PDF 61.6 KB Add to Briefcase
View Summary Aradigm to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29
Sep 23, 2015
PDF 12.3 KB Add to Briefcase
Showing 1-20 of 212 Page: 1 2 3 ... 11  Next 20
= add release to Briefcase
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2016 Aradigm Corporation. All Rights Reserved.